ifosfamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives	1421	3778-73-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ifosfamide holoxan ifomide ifosfamid ifosfomide ifosphamide iphosphamide isoendoxan isofosfamide isophosphamide mitoxana naxamide	Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Molecular weight: 261.08 Formula: C7H15Cl2N2O2P CLOGP: 0.92 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 41.57 ALOGS: -1.24 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ifosfamide
holoxan
ifomide
ifosfamid
ifosfomide
ifosphamide
iphosphamide
isoendoxan
isofosfamide
isophosphamide
mitoxana
naxamide

Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.

Molecular weight: 261.08
Formula: C7H15Cl2N2O2P
CLOGP: 0.92
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 41.57
ALOGS: -1.24
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	100 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	113.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	92 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.62 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 30, 1988	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1049.35	24.38	522	13765	97145	50493692
Encephalopathy	737.29	24.38	297	13990	33414	50557423
Neutropenia	556.86	24.38	403	13884	147562	50443275
Mucosal inflammation	433.48	24.38	216	14071	39926	50550911
Myelodysplastic syndrome	417.56	24.38	158	14129	14974	50575863
Ovarian failure	414.27	24.38	89	14198	1022	50589815
Bone marrow failure	397.01	24.38	181	14106	27443	50563394
Acute myeloid leukaemia	336.55	24.38	135	14152	14939	50575898
Off label use	277.40	24.38	485	13802	473941	50116896
Thrombocytopenia	275.74	24.38	252	14035	127421	50463416
Product use in unapproved indication	256.68	24.38	232	14055	115587	50475250
Pancytopenia	221.68	24.38	186	14101	83844	50506993
Neurotoxicity	203.48	24.38	94	14193	14646	50576191
Haematotoxicity	191.11	24.38	75	14212	7820	50583017
Myelosuppression	182.84	24.38	85	14202	13432	50577405
Disease progression	172.02	24.38	171	14116	95695	50495142
Febrile bone marrow aplasia	159.98	24.38	62	14225	6249	50584588
Malignant neoplasm progression	157.65	24.38	140	14147	67984	50522853
Cardiotoxicity	156.97	24.38	63	14224	6964	50583873
Second primary malignancy	154.49	24.38	62	14225	6852	50583985
Toxic encephalopathy	135.61	24.38	53	14234	5462	50585375
Aplasia	127.87	24.38	46	14241	3767	50587070
Diffuse large B-cell lymphoma recurrent	100.67	24.38	31	14256	1564	50589273
Fanconi syndrome	93.04	24.38	27	14260	1109	50589728
Anaemia	88.87	24.38	210	14077	252246	50338591
Leukopenia	81.72	24.38	98	14189	67430	50523407
Premature menopause	79.25	24.38	22	14265	768	50590069
Cystitis haemorrhagic	78.57	24.38	32	14255	3670	50587167
Arthralgia	77.61	24.38	15	14272	438687	50152150
Diffuse large B-cell lymphoma refractory	73.15	24.38	22	14265	1024	50589813
Metastases to lymph nodes	64.64	24.38	34	14253	6990	50583847
Posterior reversible encephalopathy syndrome	63.48	24.38	44	14243	14884	50575953
Septic shock	61.15	24.38	78	14209	57097	50533740
Pain	60.89	24.38	45	14242	578858	50011979
Gene mutation	60.79	24.38	20	14267	1251	50589586
Ovarian disorder	59.37	24.38	17	14270	665	50590172
Nephrogenic diabetes insipidus	59.33	24.38	18	14269	863	50589974
Renal tubular disorder	58.42	24.38	23	14264	2414	50588423
Fatigue	55.91	24.38	71	14216	707530	49883307
Neutropenic sepsis	53.91	24.38	39	14248	14108	50576729
Nephropathy toxic	52.38	24.38	31	14256	7998	50582839
Ascites	51.70	24.38	57	14230	35804	50555033
Oesophageal candidiasis	51.21	24.38	26	14261	4968	50585869
Leukoerythroblastosis	50.29	24.38	12	14275	226	50590611
Salivary gland cancer	48.70	24.38	11	14276	161	50590676
Headache	48.69	24.38	43	14244	506492	50084345
Fall	48.60	24.38	17	14270	334915	50255922
Leukoencephalopathy	48.12	24.38	23	14264	3860	50586977
Pruritus	47.39	24.38	11	14276	283557	50307280
Platelet count decreased	46.97	24.38	94	14193	100632	50490205
Rash	45.93	24.38	34	14253	437437	50153400
Malignant transformation	45.50	24.38	12	14275	344	50590493
Metastases to peritoneum	45.20	24.38	20	14267	2813	50588024
Abdominal discomfort	45.19	24.38	6	14281	231635	50359202
Vena cava thrombosis	44.71	24.38	18	14269	2003	50588834
Neutrophil count decreased	43.34	24.38	59	14228	45967	50544870
Metastases to breast	43.26	24.38	11	14276	272	50590565
Dizziness	43.17	24.38	22	14265	346347	50244490
Weight increased	42.47	24.38	4	14283	201887	50388950
Deafness	41.81	24.38	35	14252	15656	50575181
Myeloid leukaemia	41.65	24.38	11	14276	317	50590520
Pyrexia	40.01	24.38	212	14075	379991	50210846
Disease recurrence	40.00	24.38	38	14249	20043	50570794
Periorbital cellulitis	39.68	24.38	12	14275	569	50590268
Pneumothorax	38.84	24.38	32	14255	14002	50576835
White blood cell count abnormal	38.11	24.38	22	14265	5418	50585419
Neoplasm progression	38.03	24.38	44	14243	29113	50561724
Haemophagocytic lymphohistiocytosis	38.00	24.38	26	14261	8607	50582230
Drug hypersensitivity	37.68	24.38	12	14275	250998	50339839
Cough	37.17	24.38	11	14276	241253	50349584
Dyspnoea	36.25	24.38	62	14225	547546	50043291
Amniotic fluid index decreased	36.13	24.38	6	14281	13	50590824
Pain in extremity	36.02	24.38	16	14271	272849	50317988
Neoplasm recurrence	35.47	24.38	16	14271	2353	50588484
Insomnia	35.39	24.38	4	14283	174861	50415976
Subdural hygroma	34.78	24.38	9	14278	239	50590598
Oligohydramnios	34.40	24.38	21	14266	5729	50585108
Sinusitis	34.27	24.38	4	14283	170554	50420283
Drug resistance	34.20	24.38	34	14253	18955	50571882
Amenorrhoea	33.72	24.38	24	14263	8460	50582377
Vulvovaginitis	32.65	24.38	9	14278	306	50590531
Therapy partial responder	31.77	24.38	21	14266	6570	50584267
Malaise	31.55	24.38	29	14258	335503	50255334
Abdominal pain upper	31.36	24.38	4	14283	159305	50431532
Swelling	31.22	24.38	9	14278	200863	50389974
Contraindicated product administered	31.19	24.38	3	14284	148955	50441882
Cytokine release syndrome	31.08	24.38	23	14264	8611	50582226
Hypersensitivity	31.04	24.38	11	14276	215150	50375687
Stem cell transplant	30.61	24.38	13	14274	1655	50589182
Systemic candida	30.00	24.38	15	14272	2775	50588062
Systemic lupus erythematosus	29	24.38	3	14284	140619	50450218
Skin turgor decreased	28.74	24.38	9	14278	480	50590357
Cytopenia	28.54	24.38	22	14265	8753	50582084
Blood stem cell transplant failure	28.44	24.38	7	14280	151	50590686
Rectal fissure	28.09	24.38	9	14278	517	50590320
Paranasal sinus mucosal hypertrophy	27.63	24.38	5	14282	21	50590816
Candida test positive	27.38	24.38	10	14277	854	50589983
Rhabdomyosarcoma recurrent	27.26	24.38	5	14282	23	50590814
Tumour lysis syndrome	27.23	24.38	20	14267	7401	50583436
Fanconi syndrome acquired	26.74	24.38	10	14277	913	50589924
Thymus enlargement	26.18	24.38	6	14281	94	50590743
Delayed puberty	26.01	24.38	6	14281	97	50590740
Escherichia bacteraemia	25.63	24.38	14	14273	3102	50587735
Infusion related reaction	25.61	24.38	8	14279	169549	50421288
Sepsis	25.48	24.38	89	14198	132836	50458001
Myelopathy	25.29	24.38	13	14274	2548	50588289
Condition aggravated	25.26	24.38	28	14259	297030	50293807
Gastrointestinal toxicity	25.24	24.38	16	14271	4661	50586176
Vascular compression	24.90	24.38	6	14281	118	50590719

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1055.21	20.12	743	18792	111497	29443495
Encephalopathy	458.49	20.12	274	19261	30769	29524223
Neutropenia	413.61	20.12	470	19065	131241	29423751
Myelodysplastic syndrome	348.53	20.12	189	19346	17605	29537387
Off label use	334.12	20.12	658	18877	300142	29254850
Bone marrow failure	299.12	20.12	200	19335	27249	29527743
Acute myeloid leukaemia	270.47	20.12	156	19379	16357	29538635
Product use in unapproved indication	235.36	20.12	288	19247	86587	29468405
Mucosal inflammation	225.05	20.12	178	19357	31417	29523575
Thrombocytopenia	222.62	20.12	352	19183	134471	29420521
Myelosuppression	190.86	20.12	112	19423	12115	29542877
Diffuse large B-cell lymphoma recurrent	187.75	20.12	69	19466	2528	29552464
Malignant neoplasm progression	167.00	20.12	224	19311	73635	29481357
Pancytopenia	166.73	20.12	238	19297	82930	29472062
Diffuse large B-cell lymphoma refractory	166.67	20.12	49	19486	873	29554119
Disease progression	165.07	20.12	235	19300	81681	29473311
Second primary malignancy	158.99	20.12	81	19454	6624	29548368
Haematotoxicity	141.82	20.12	75	19460	6624	29548368
Cytopenia	140.03	20.12	85	19450	9774	29545218
Neurotoxicity	132.07	20.12	95	19440	14518	29540474
Toxic encephalopathy	127.95	20.12	62	19473	4550	29550442
Renal tubular disorder	107.33	20.12	54	19481	4298	29550694
Fanconi syndrome	106.49	20.12	40	19495	1558	29553434
Leukopenia	98.94	20.12	150	19385	55053	29499939
Febrile bone marrow aplasia	95.79	20.12	60	19475	7291	29547701
Salivary gland cancer	93.84	20.12	24	19511	246	29554746
Neutropenic sepsis	91.94	20.12	70	19465	11657	29543335
Osteosarcoma	90.35	20.12	22	19513	181	29554811
Fall	87.87	20.12	8	19527	177170	29377822
Aplasia	79.01	20.12	43	19492	4020	29550972
Neoplasm progression	74.84	20.12	76	19459	18536	29536456
Cystitis haemorrhagic	74.59	20.12	44	19491	4798	29550194
Stomatitis	73.89	20.12	106	19429	37007	29517985
Neoplasm recurrence	71.69	20.12	32	19503	1945	29553047
Therapy partial responder	69.15	20.12	43	19492	5156	29549836
Nephropathy toxic	64.73	20.12	55	19480	10701	29544291
Sepsis	64.61	20.12	224	19311	142458	29412534
Malignant transformation	63.39	20.12	23	19512	811	29554181
Blood stem cell transplant failure	61.68	20.12	19	19516	399	29554593
Cardiotoxicity	55.05	20.12	36	19499	4708	29550284
Myocardial infarction	54.58	20.12	5	19530	110291	29444701
Disease recurrence	53.35	20.12	59	19476	15855	29539137
Metastases to lung	53.16	20.12	43	19492	7812	29547180
Metastases to muscle	50.04	20.12	14	19521	207	29554785
Nervous system disorder	49.57	20.12	51	19484	12623	29542369
Venoocclusive liver disease	49.23	20.12	39	19496	6878	29548114
Acute lymphocytic leukaemia	48.82	20.12	27	19508	2604	29552388
Cellulitis gangrenous	47.25	20.12	13	19522	180	29554812
Delayed puberty	46.92	20.12	13	19522	185	29554807
Anaemia	45.94	20.12	257	19278	200694	29354298
Transformation to acute myeloid leukaemia	44.87	20.12	17	19518	678	29554314
Dizziness	44.60	20.12	36	19499	189648	29365344
Body height below normal	44.56	20.12	13	19522	225	29554767
Ganglioneuroblastoma	44.45	20.12	9	19526	27	29554965
Insomnia	43.97	20.12	4	19531	88757	29466235
B-cell lymphoma recurrent	42.99	20.12	16	19519	607	29554385
Fanconi syndrome acquired	42.92	20.12	22	19513	1820	29553172
Azoospermia	41.68	20.12	14	19521	391	29554601
Rhabdomyosarcoma recurrent	40.47	20.12	10	19525	88	29554904
Encephalitis enteroviral	40.41	20.12	11	19524	146	29554846
Device related infection	39.23	20.12	50	19485	15586	29539406
Fatigue	38.79	20.12	96	19439	316725	29238267
Septic shock	38.16	20.12	109	19426	62451	29492541
Cardiac failure congestive	36.49	20.12	4	19531	76577	29478415
Metastases to retroperitoneum	36.40	20.12	11	19524	216	29554776
Hepatitis B reactivation	36.24	20.12	24	19511	3205	29551787
Ameloblastoma	35.85	20.12	9	19526	85	29554907
Meningitis tuberculous	35.75	20.12	14	19521	611	29554381
Rash	35.48	20.12	44	19491	189775	29365217
Pyrexia	35.18	20.12	316	19219	287306	29267686
Lymphopenia	35.10	20.12	44	19491	13489	29541503
Myalgia	34.93	20.12	4	19531	74015	29480977
Metastases to spleen	34.66	20.12	12	19523	368	29554624
Autoimmune neutropenia	34.32	20.12	11	19524	264	29554728
Therapy non-responder	33.09	20.12	67	19468	30844	29524148
Ototoxicity	31.64	20.12	17	19518	1548	29553444
Posterior reversible encephalopathy syndrome	31.33	20.12	34	19501	8942	29546050
Hypophosphataemia	31.19	20.12	32	19503	7892	29547100
Recurrent cancer	30.33	20.12	15	19520	1150	29553842
Tumour lysis syndrome	29.60	20.12	41	19494	13843	29541149
Depression	29.03	20.12	10	19525	85137	29469855
Tubulointerstitial nephritis	28.84	20.12	46	19489	17597	29537395
Venoocclusive disease	28.81	20.12	19	19516	2520	29552472
Malaise	28.77	20.12	38	19497	159564	29395428
Nasopharyngitis	28.72	20.12	3	19532	59662	29495330
Dyspnoea	28.69	20.12	115	19420	326617	29228375
Progressive multifocal leukoencephalopathy	28.66	20.12	32	19503	8687	29546305
Drug resistance	28.37	20.12	51	19484	21489	29533503
Cytokine release syndrome	28.35	20.12	39	19496	13080	29541912
Metastases to bone marrow	28.29	20.12	11	19524	471	29554521
Blood pressure increased	28.21	20.12	7	19528	73796	29481196
BK virus infection	28.17	20.12	24	19511	4683	29550309
Bradycardia	27.59	20.12	5	19530	65624	29489368
Basal cell naevus syndrome	27.21	20.12	6	19529	30	29554962
Treatment failure	27.18	20.12	69	19466	36870	29518122
Syncope	26.98	20.12	10	19525	81361	29473631
Clostridium difficile colitis	26.65	20.12	38	19497	13174	29541818
Chest pain	26.59	20.12	21	19514	111952	29443040
Peripheral swelling	26.48	20.12	5	19530	63734	29491258
Lymphadenopathy	26.46	20.12	54	19481	24995	29529997
Scedosporium infection	26.22	20.12	12	19523	773	29554219
Pain	25.91	20.12	46	19489	171386	29383606
Diffuse large B-cell lymphoma	25.90	20.12	26	19509	6250	29548742
Herpes simplex	25.39	20.12	23	19512	4867	29550125
Human herpesvirus 8 infection	25.35	20.12	12	19523	835	29554157
Hyperkalaemia	25.12	20.12	5	19530	61387	29493605
Neutropenic colitis	24.85	20.12	17	19518	2394	29552598
Overdose	24.53	20.12	11	19524	79808	29475184
Arthralgia	24.38	20.12	34	19501	139583	29415409
Renal tubular injury	24.24	20.12	11	19524	695	29554297
Angiodysplasia	24.15	20.12	10	19525	505	29554487
Myeloid leukaemia	24.09	20.12	9	19526	345	29554647
Staphylococcal infection	24.04	20.12	57	19478	29183	29525809
Synovial sarcoma metastatic	24.00	20.12	5	19530	18	29554974
Headache	23.43	20.12	50	19485	173957	29381035
Chromosome analysis abnormal	23.28	20.12	7	19528	135	29554857
Back pain	23.27	20.12	20	19515	102264	29452728
Vena cava thrombosis	23.26	20.12	12	19523	1006	29553986
Blastic plasmacytoid dendritic cell neoplasia	23.24	20.12	6	19529	64	29554928
Feeling abnormal	23.20	20.12	4	19531	54441	29500551
Large intestine infection	23.05	20.12	13	19522	1302	29553690
Weight increased	22.89	20.12	11	19524	76656	29478336
Bone sarcoma	22.75	20.12	6	19529	70	29554922
Salivary gland neoplasm	22.67	20.12	5	19530	25	29554967
Bladder spasm	22.50	20.12	11	19524	822	29554170
Aspergillus infection	22.18	20.12	31	19504	10550	29544442
Bacteraemia	21.94	20.12	39	19496	16284	29538708
Subdural hygroma	21.81	20.12	8	19527	291	29554701
Muscle spasms	21.57	20.12	8	19527	65074	29489918
Asthenia	21.32	20.12	72	19463	215178	29339814
Intussusception	20.54	20.12	9	19526	523	29554469
Agranulocytosis	20.48	20.12	43	19492	20297	29534695
Systemic candida	20.48	20.12	16	19519	2764	29552228
Stem cell transplant	20.46	20.12	14	19521	1973	29553019
Hospitalisation	20.45	20.12	3	19532	45985	29509007
Anxiety	20.27	20.12	16	19519	85349	29469643

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	1839.67	19.84	1127	29500	186530	64281575
Encephalopathy	1038.34	19.84	522	30105	58297	64409808
Neutropenia	852.35	19.84	785	29842	238839	64229266
Myelodysplastic syndrome	657.03	19.84	301	30326	27278	64440827
Bone marrow failure	633.64	19.84	351	30276	47601	64420504
Acute myeloid leukaemia	535.12	19.84	261	30366	27202	64440903
Mucosal inflammation	527.30	19.84	343	30284	62241	64405864
Off label use	495.13	19.84	987	29640	631819	63836286
Thrombocytopenia	432.50	19.84	531	30096	223270	64244835
Product use in unapproved indication	373.60	19.84	439	30188	176179	64291926
Pancytopenia	357.15	19.84	388	30239	142921	64325184
Malignant neoplasm progression	330.16	19.84	333	30294	112538	64355567
Neurotoxicity	301.08	19.84	178	30449	27226	64440879
Haematotoxicity	298.29	19.84	138	30489	12758	64455347
Second primary malignancy	291.55	19.84	134	30493	12203	64455902
Myelosuppression	283.51	19.84	163	30464	23667	64444438
Disease progression	268.01	19.84	333	30294	141347	64326758
Diffuse large B-cell lymphoma recurrent	232.11	19.84	78	30549	3068	64465037
Toxic encephalopathy	226.88	19.84	105	30522	9710	64458395
Febrile bone marrow aplasia	225.19	19.84	109	30518	11146	64456959
Fanconi syndrome	212.55	19.84	69	30558	2432	64465673
Cardiotoxicity	192.07	19.84	95	30532	10179	64457926
Aplasia	188.03	19.84	83	30544	6870	64461235
Leukopenia	167.75	19.84	223	30404	101019	64367086
Renal tubular disorder	160.39	19.84	71	30556	5916	64462189
Cytopenia	145.48	19.84	91	30536	15380	64452725
Salivary gland cancer	137.49	19.84	33	30594	366	64467739
Fall	134.93	19.84	19	30608	416807	64051298
Diffuse large B-cell lymphoma refractory	133.23	19.84	40	30587	1084	64467021
Cystitis haemorrhagic	132.39	19.84	68	30559	7888	64460217
Anaemia	122.24	19.84	426	30201	378254	64089851
Neutropenic sepsis	120.55	19.84	95	30532	23177	64444928
Nephropathy toxic	105.00	19.84	78	30549	17436	64450669
Osteosarcoma	103.85	19.84	25	30602	281	64467824
Arthralgia	102.50	19.84	41	30586	442219	64025886
Malignant transformation	99.07	19.84	32	30595	1109	64466996
Neoplasm progression	96.71	19.84	108	30519	40856	64427249
Fatigue	95.58	19.84	130	30497	748600	63719505
Pain	89.43	19.84	79	30548	553432	63914673
Sepsis	88.37	19.84	275	30352	230066	64238039
Therapy partial responder	85.72	19.84	56	30571	10192	64457913
Septic shock	85.68	19.84	168	30459	105269	64362836
Posterior reversible encephalopathy syndrome	84.54	19.84	77	30550	22869	64445236
Dizziness	84.28	19.84	50	30577	430113	64037992
Peripheral swelling	79.52	19.84	5	30622	209148	64258957
Product dose omission issue	79.32	19.84	3	30624	194744	64273361
Pyrexia	78.04	19.84	492	30135	558152	63909953
Neoplasm recurrence	77.16	19.84	37	30590	3702	64464403
Blood stem cell transplant failure	76.41	19.84	22	30605	513	64467592
Metastases to lymph nodes	76.27	19.84	49	30578	8668	64459437
Cytokine release syndrome	74.98	19.84	69	30558	20760	64447345
Disease recurrence	74.24	19.84	83	30544	31427	64436678
Nasopharyngitis	73.61	19.84	5	30622	196068	64272037
Metastases to lung	72.00	19.84	59	30568	15205	64452900
Rash	69.81	19.84	69	30558	458480	64009625
Myeloid leukaemia	69.32	19.84	21	30606	587	64467518
Fanconi syndrome acquired	69.02	19.84	30	30597	2391	64465714
Insomnia	68.89	19.84	7	30620	197829	64270276
Abdominal discomfort	67.43	19.84	5	30622	182317	64285788
Stomatitis	64.20	19.84	153	30474	109452	64358653
Headache	63.39	19.84	96	30531	529371	63938734
Malaise	62.18	19.84	58	30569	396189	64071916
Ovarian disorder	61.44	19.84	18	30609	447	64467658
Acute lymphocytic leukaemia	60.38	19.84	33	30594	4338	64463767
Weight increased	59.73	19.84	14	30613	213334	64254771
Rhabdomyosarcoma recurrent	59.63	19.84	13	30614	90	64468015
B-cell lymphoma recurrent	58.89	19.84	20	30607	812	64467293
Premature menopause	58.65	19.84	18	30609	526	64467579
Drug hypersensitivity	58.45	19.84	20	30607	237795	64230310
Lymphopenia	57.74	19.84	66	30561	25591	64442514
Dyspnoea	57.60	19.84	164	30463	718510	63749595
Subdural hygroma	57.32	19.84	17	30610	441	64467664
Myocardial infarction	54.88	19.84	7	30620	165814	64302291
Delayed puberty	54.42	19.84	13	30614	141	64467964
Drug resistance	53.02	19.84	74	30553	35028	64433077
Venoocclusive disease	52.06	19.84	29	30598	3956	64464149
Pneumothorax	50.50	19.84	60	30567	24238	64443867
Metastases to muscle	49.22	19.84	14	30613	312	64467793
Systemic candida	49.22	19.84	31	30596	5298	64462807
Tumour lysis syndrome	48.89	19.84	53	30574	19387	64448718
Metastases to breast	48.43	19.84	13	30614	232	64467873
Stem cell transplant	47.31	19.84	26	30601	3455	64464650
Ganglioneuroblastoma	46.93	19.84	9	30618	29	64468076
Pain in extremity	46.76	19.84	45	30582	303040	64165065
Cough	46.46	19.84	45	30582	302103	64166002
Leukoencephalopathy	46.23	19.84	33	30594	6934	64461171
Pruritus	45.23	19.84	49	30578	312351	64155754
Progressive multifocal leukoencephalopathy	44.62	19.84	49	30578	18183	64449922
Recurrent cancer	44.51	19.84	22	30605	2351	64465754
Encephalitis enteroviral	44.29	19.84	11	30616	142	64467963
Haemophagocytic lymphohistiocytosis	44.27	19.84	48	30579	17561	64450544
Gene mutation	44.17	19.84	21	30606	2061	64466044
Hepatitis B reactivation	44.05	19.84	28	30599	4861	64463244
Musculoskeletal stiffness	43.82	19.84	4	30623	123202	64344903
Leukoerythroblastosis	43.32	19.84	12	30615	242	64467863
Myalgia	43.22	19.84	11	30616	158606	64309499
Nephrogenic diabetes insipidus	43.01	19.84	20	30607	1867	64466238
Arachnoiditis	42.71	19.84	15	30612	674	64467431
Contusion	42.48	19.84	3	30624	113962	64354143
Cellulitis gangrenous	42.17	19.84	12	30615	268	64467837
Cardiac failure congestive	42.04	19.84	6	30621	130574	64337531
Blood pressure increased	41.54	19.84	15	30612	172537	64295568
Injection site pain	41.33	19.84	3	30624	111405	64356700
Device related infection	41.04	19.84	61	30566	30565	64437540
Abdominal pain upper	40.82	19.84	16	30611	175014	64293091
Urticaria	40.56	19.84	10	30617	147307	64320798
Platelet count decreased	40.22	19.84	172	30455	167539	64300566
Chest pain	40.06	19.84	32	30595	235948	64232157
Venoocclusive liver disease	39.63	19.84	35	30592	9980	64458125
Neutrophil count decreased	39.11	19.84	102	30525	77094	64391011
Metastases to peritoneum	38.82	19.84	23	30604	3524	64464581
Ameloblastoma	38.80	19.84	9	30618	85	64468020
Hypersensitivity	38.16	19.84	23	30604	196429	64271676
Cardiomyopathy	37.62	19.84	53	30574	25303	64442802
Swelling	36.78	19.84	15	30612	160203	64307902
Urinary tract infection	36.16	19.84	34	30593	231562	64236543
Metastases to bone marrow	35.59	19.84	13	30614	655	64467450
Palpitations	35.58	19.84	4	30623	104484	64363621
Therapeutic product effect decreased	35.54	19.84	6	30621	115345	64352760
Metastases to liver	35.45	19.84	50	30577	23891	64444214
Metastases to spleen	35.17	19.84	12	30615	494	64467611
Condition aggravated	35.16	19.84	78	30549	372348	64095757
Renal impairment	35.13	19.84	142	30485	134875	64333230
Renal tubular injury	35.11	19.84	15	30612	1146	64466959
Metastases to retroperitoneum	34.60	19.84	11	30616	362	64467743
Sinusitis	34.59	19.84	13	30614	145915	64322190
Muscle spasms	34.38	19.84	12	30615	141011	64327094
Candida infection	34.35	19.84	57	30570	31362	64436743
Ejection fraction decreased	34.00	19.84	54	30573	28653	64439452
Nervous system disorder	33.88	19.84	48	30579	23030	64445075
Anxiety	33.74	19.84	28	30599	202621	64265484
Agranulocytosis	33.58	19.84	63	30564	38166	64429939
Autoimmune neutropenia	33.37	19.84	11	30616	407	64467698
Multiple organ dysfunction syndrome	33.34	19.84	115	30512	101298	64366807
Amniotic fluid index decreased	33.01	19.84	6	30621	13	64468092
Inappropriate schedule of product administration	32.80	19.84	3	30624	92283	64375822
Meningitis tuberculous	32.43	19.84	14	30613	1097	64467008
Back pain	32.19	19.84	43	30584	250128	64217977
Staphylococcal infection	32.11	19.84	73	30554	50605	64417500
Myelitis	32.11	19.84	17	30610	2097	64466008
Arthropathy	31.80	19.84	9	30618	120958	64347147
Oesophageal candidiasis	31.69	19.84	28	30599	7989	64460116
Synovial sarcoma	31.33	19.84	7	30620	55	64468050
Diffuse large B-cell lymphoma	30.99	19.84	31	30596	10330	64457775
Infusion related reaction	30.91	19.84	20	30607	164447	64303658
Periorbital cellulitis	30.47	19.84	12	30615	744	64467361
Hypophosphataemia	30.01	19.84	36	30591	14684	64453421
Azoospermia	29.90	19.84	8	30619	141	64467964
Rhabdomyosarcoma	29.79	19.84	8	30619	143	64467962
Influenza	29.77	19.84	7	30620	106524	64361581
Depression	29.68	19.84	26	30601	183265	64284840
Basal cell naevus syndrome	29.18	19.84	6	30621	30	64468075
Transformation to acute myeloid leukaemia	28.96	19.84	12	30615	849	64467256
Vulvovaginitis	28.94	19.84	9	30618	275	64467830
Neutropenic colitis	28.80	19.84	21	30606	4560	64463545
Bronchitis	28.75	19.84	8	30619	108735	64359370
Aspergillus infection	28.50	19.84	37	30590	16342	64451763
Salivary gland neoplasm	28.07	19.84	7	30620	92	64468013
White blood cell count decreased	27.74	19.84	148	30479	157689	64310416
Bradycardia	27.24	19.84	11	30616	118208	64349897
Herpes simplex	26.97	19.84	29	30598	10507	64457598
Deafness	26.68	19.84	38	30589	18321	64449784
Overdose	26.61	19.84	22	30605	159544	64308561
Quadriplegia	26.51	19.84	17	30610	2996	64465109
Human herpesvirus 8 infection	26.42	19.84	12	30615	1061	64467044
Blood glucose increased	26.33	19.84	7	30620	98066	64370039
Hypoalbuminaemia	26.30	19.84	37	30590	17637	64450468
Synovial sarcoma metastatic	26.10	19.84	5	30622	16	64468089
Infection	25.75	19.84	163	30464	184717	64283388
Hyperkalaemia	25.71	19.84	8	30619	101121	64366984
BK virus infection	25.60	19.84	24	30603	7388	64460717
Musculoskeletal pain	25.55	19.84	4	30623	81290	64386815
Therapy non-responder	25.49	19.84	79	30548	65820	64402285
Discomfort	25.38	19.84	4	30623	80874	64387231
Hospitalisation	25.30	19.84	3	30624	75204	64392901
Mobility decreased	25.29	19.84	5	30622	85835	64382270
Hyperhidrosis	25.14	19.84	14	30613	124906	64343199
Tubulointerstitial nephritis	24.77	19.84	49	30578	30860	64437245
Sarcoma metastatic	24.72	19.84	6	30621	70	64468035
Scedosporium infection	24.64	19.84	12	30615	1242	64466863
Myelopathy	24.49	19.84	18	30609	3956	64464149
Hypoacusis	24.44	19.84	44	30583	25823	64442282
Encephalitis cytomegalovirus	23.99	19.84	11	30616	994	64467111
Recall phenomenon	23.98	19.84	11	30616	995	64467110
Disorientation	23.54	19.84	69	30558	55759	64412346
Oligohydramnios	23.54	19.84	16	30611	3108	64464997
Ototoxicity	23.06	19.84	15	30612	2708	64465397
Dyspepsia	23.00	19.84	5	30622	80307	64387798
Osteonecrosis	22.92	19.84	45	30582	28184	64439921
Mucoepidermoid carcinoma of salivary gland	22.85	19.84	6	30621	98	64468007
Transdifferentiation of neoplasm	22.85	19.84	6	30621	98	64468007
Myoclonus	22.81	19.84	42	30585	25076	64443029
Angiodysplasia	22.74	19.84	10	30617	819	64467286
Hypogammaglobulinaemia	22.34	19.84	26	30601	10273	64457832
Asthenia	22.32	19.84	116	30511	427928	64040177
Amenorrhoea	22.25	19.84	21	30606	6518	64461587
Erythropenia	22.21	19.84	8	30619	387	64467718
Chest discomfort	21.97	19.84	14	30613	116092	64352013
Gastrointestinal toxicity	21.86	19.84	19	30608	5303	64462802
Clostridium difficile infection	21.71	19.84	51	30576	36112	64431993
Skin turgor decreased	21.68	19.84	9	30618	640	64467465
Polyneuropathy	21.62	19.84	36	30591	19858	64448247
Escherichia bacteraemia	21.61	19.84	19	30608	5384	64462721
Oxygen saturation decreased	21.58	19.84	12	30615	107164	64360941
Feeling abnormal	21.57	19.84	19	30608	133583	64334522
Diabetes mellitus	21.52	19.84	3	30624	66471	64401634
Haematochezia	21.48	19.84	3	30624	66370	64401735
Cardio-respiratory arrest	21.33	19.84	10	30617	98383	64369722
Epstein Barr virus positive mucocutaneous ulcer	21.06	19.84	9	30618	688	64467417
Metastasis	20.75	19.84	19	30608	5676	64462429
Gait disturbance	20.73	19.84	31	30596	172124	64295981
Balance disorder	20.70	19.84	7	30620	83919	64384186
Cerebrovascular accident	20.53	19.84	21	30606	137562	64330543
Syncope	20.36	19.84	27	30600	157608	64310497
Candida test positive	20.31	19.84	10	30617	1060	64467045
Rectal fissure	20.25	19.84	9	30618	756	64467349
Fungal infection	20.23	19.84	48	30579	34203	64433902
Endometrial disorder	20.21	19.84	8	30619	503	64467602
Pneumocystis jirovecii pneumonia	20.00	19.84	42	30585	27592	64440513
Asterixis	19.97	19.84	13	30614	2350	64465755

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01AA06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues
FDA MoA	N0000000236	Alkylating Activity
FDA EPC	N0000175558	Alkylating Drug
MeSH PA	D000477	Alkylating Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018906	Antineoplastic Agents, Alkylating
MeSH PA	D009676	Noxae
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35705	immunosuppressive agents
CHEBI has role	CHEBI:78298	environmental contaminants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Testicular Germ Cell Tumor	indication
Ewing's sarcoma	off-label use	76909002	DOID:3369
Burkitt's lymphoma	off-label use	118617000
Small cell carcinoma of lung	off-label use	254632001	DOID:5409
Non-small cell lung cancer	off-label use	254637007	DOID:3908
Malignant tumor of head and/or neck	off-label use	255056009
Osteosarcoma of bone	off-label use	307576001	DOID:3376
Soft or Connective Tissue Sarcoma	off-label use
Progressive Diffuse Large B-Cell Lymphoma	off-label use
Invasive Bladder Malignancy	off-label use
Renal tubular acidosis	contraindication	1776003	DOID:14219
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Dehydration	contraindication	34095006
Fanconi syndrome	contraindication	40488004	DOID:1062
Hypokalemia	contraindication	43339004
Leukopenia	contraindication	84828003	DOID:615
Kidney disease	contraindication	90708001	DOID:557
Kidney excision	contraindication	108022006
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Impaired wound healing	contraindication	271618001
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Bone marrow depression	contraindication	307762000
Coma	contraindication	371632003
Impaired cognition	contraindication	386806002
Breastfeeding (mother)	contraindication	413712001
Polyneuropathies	contraindication
CNS Toxicity	contraindication
Cancer Chemotherapy Induced Hemorrhagic Cystitis	contraindication
Severe Bone Marrow Depression	contraindication
Bone Metastases	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.54	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4019476	VUID
N0000147596	NUI
D00343	KEGG_DRUG
4019476	VANDF
C0020823	UMLSCUI
CHEBI:5864	CHEBI
CHEMBL1024	ChEMBL_ID
DB01181	DRUGBANK_ID
D007069	MESH_DESCRIPTOR_UI
3690	PUBCHEM_CID
7201	IUPHAR_LIGAND_ID
2865	INN_ID
UM20QQM95Y	UNII
5657	RXNORM
44391	MMSL
4867	MMSL
d00257	MMSL
002642	NDDF
108757000	SNOMEDCT_US
386904003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9530	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9531	INJECTION	50 mg	INTRAVENOUS	ANDA	25 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3991	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFEX	HUMAN PRESCRIPTION DRUG LABEL	1	0338-3993	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3427	INJECTION, SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ifosfamide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-3429	INJECTION, SOLUTION	3 g	INTRAVENOUS	ANDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-925	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-926	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-927	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	NDA	26 sections
IFOSFAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-929	INJECTION, POWDER, FOR SOLUTION	3 g	INTRAVENOUS	NDA	26 sections
Ifosfamide	Human Prescription Drug Label	1	63323-142	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Ifosfamide	Human Prescription Drug Label	1	63323-142	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections